Determination of a whole-blood single-test low-risk threshold for a point-of-care high-sensitivity troponin assay

High-sensitivity troponin (hsTn) is used with ECG and clinical evaluation to stratify patients attending ED as low risk for acute myocardial infarctions (AMI). Diagnostic pathways incorporate a single test threshold for stratification with these assays. The Siemens Atellica VTLi Point-Of-Care-hsTnI assay (POC-hsTnI) has an 8 min turn-around which may expedite decision-making. Although a single-test low-risk (‘rule-out’) threshold for this assay has been reported,1 it was desirable to determine a threshold specifically for New Zealand ED settings and intended end-users. From 3 November 2022 to 28 May 2023, hsTnI was measured by POC-hsTnI and laboratory (Beckman Coulter DXI800) assays from one venous blood draw into a single lithium heparin tube. The whole-blood limit of detection (LoD) of the POC-hsTnI is 1.6 ng/L, and the 10% and 20% coefficient of variations (CVs) are 8.9 ng/L and 3.7 ng/L.2 3 The Beckman assay plasma LoD and 20%...
Source: Emergency Medicine Journal - Category: Emergency Medicine Authors: Tags: Research letter Source Type: research